Search
SOLACI Congress
HomeCONGRESS

CONGRESS

View Category
Day 2

Negative ultrasensitive troponin T values may help discriminate patients with chest pain in the emergency

New laboratory tests can detect minimally elevated  levels few hours before regarding detection methodologies of previous generations.The...
solaci -
Learn More
Day 2

LAPLACE 2: Evolocumab effective in reducing LDL associated with statins

There are several patients who do not reach recommended LDL cholesterol despite maximally tolerated doses of statins...
solaci -
Learn More
Day 2

MADIT -CRT: Increased survival with resynchronization therapy plus defibrillator in patients with mild heart failure.

The MADIT -CRT study (Multicenter Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy) had shown that early intervention...
solaci -
Learn More
Day 2

Global Registry SYMPLICITY demonstrated the safety of renal denervation system

The Global SYMPLICITY registry is a prospective, multicenter study sponsored by Medtronic to evaluate long- term renal...
solaci -
Learn More
Day 2

GAUSS -2: Evolocumab effective in reducing LDL cholesterol in patients intolerant to statins

Adverse effects of statins are relatively common causing poor adherence to treatment and the need for interruption...
solaci -
Learn More
Day 2

ALECARDIO Trial: Aleglitazar associated with severe adverse events in diabetic patients with acute coronary syndrome

This randomized, double-blind, placebo-controlled, multicenter work evaluated the potential cardiovascular reduction risk and the long-term safety profile...
solaci -
Learn More
Day 3

POISE -2: Clonidine does not reduce the risk of perioperative death or myocardial infarction in patients undergoing noncardiac surgery

There is some evidence that clonidine administered in small doses for short periods of time prior to...
solaci -
Learn More
Day 3

COAG Trial: Dose of warfarin and Pharmacogenetics

Observational studies identified two genes that influence the dose of warfarin (CYP2C9 and VKORC1). The clinical utility...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?:

Dr. Juan Manuel Pérez - 0
Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dr. Juan Manuel Pérez - 0
Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

Dr. Omar Tupayachi - 0
The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

Institutional News

Fellow’s Corner 2026 – Submit Your Clinical Case

solaci - 0
Share your experience. Learn from experts. Grow as an interventional cardiologist. The Latin American Society of Interventional Cardiology (SOLACI) is relaunching this year the Fellow’s...

Watch Again: Cardiovascular Risk Factors in Women | SOLACI Technicians Webinar

solaci - 0
The webinar “Cardiovascular Risk Factors in Women,” held on January 27, 2026, via the Zoom platform, is now available for viewing on SOLACI’s YouTube...

Technical Training in Hemodynamics and Interventional Cardioangiology | SOLACI–CACI

solaci - 0
The SOLACI–CACI Technical Training in Hemodynamics and Interventional Cardioangiology is an academic program designed for the initial training and professional development of non-physician healthcare...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy